These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 30036569)

  • 1. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
    Sako W; Murakami N; Izumi Y; Kaji R
    J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
    Hu X; Yang Y; Gong D
    Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders.
    Constantinescu R; Rosengren L; Johnels B; Zetterberg H; Holmberg B
    Parkinsonism Relat Disord; 2010 Feb; 16(2):142-5. PubMed ID: 19647470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
    Holmberg B; Rosengren L; Karlsson JE; Johnels B
    Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
    Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
    Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurofilament heavy-chain NfH(SMI35) in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes.
    Brettschneider J; Petzold A; Süssmuth SD; Landwehrmeyer GB; Ludolph AC; Kassubek J; Tumani H
    Mov Disord; 2006 Dec; 21(12):2224-7. PubMed ID: 17013909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum NFL discriminates Parkinson disease from atypical parkinsonisms.
    Marques TM; van Rumund A; Oeckl P; Kuiperij HB; Esselink RAJ; Bloem BR; Otto M; Verbeek MM
    Neurology; 2019 Mar; 92(13):e1479-e1486. PubMed ID: 30814322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
    Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
    Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonism.
    Constantinescu R; Rosengren L; Eriksson B; Blennow K; Axelsson M
    Acta Neurol Scand; 2019 Aug; 140(2):147-156. PubMed ID: 31070772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).
    Katzdobler S; Nübling G; Klietz M; Fietzek UM; Palleis C; Bernhardt AM; Wegner F; Huber M; Rogozinski S; Schneider LS; Spruth EJ; Beyle A; Vogt IR; Brandt M; Hansen N; Glanz W; Brockmann K; Spottke A; Hoffmann DC; Peters O; Priller J; Wiltfang J; Düzel E; Schneider A; Falkenburger B; Klockgether T; Gasser T; Nuscher B; Haass C; Höglinger G; Levin J
    J Neurol; 2024 Oct; 271(10):6991-6999. PubMed ID: 39254698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.
    Santaella A; Kuiperij HB; van Rumund A; Esselink RAJ; van Gool AJ; Bloem BR; Verbeek MM
    BMC Neurol; 2020 Jan; 20(1):26. PubMed ID: 31952511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.
    Holmberg B; Johnels B; Ingvarsson P; Eriksson B; Rosengren L
    Parkinsonism Relat Disord; 2001 Sep; 8(1):23-31. PubMed ID: 11472877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again.
    Compta Y; Painous C; Soto M; Pulido-Salgado M; Fernández M; Camara A; Sánchez V; Bargalló N; Caballol N; Pont-Sunyer C; Buongiorno M; Martin N; Basora M; Tio M; Giraldo DM; Pérez-Soriano A; Zaro I; Muñoz E; Martí MJ; Valldeoriola F
    Parkinsonism Relat Disord; 2022 Jun; 99():33-41. PubMed ID: 35594661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study.
    Borm CDJM; Krismer F; Wenning GK; Seppi K; Poewe W; Pellecchia MT; Barone P; Johnsen EL; Østergaard K; Gurevich T; Djaldetti R; Sambati L; Cortelli P; Petrović I; Kostić VS; Brožová H; Růžička E; Marti MJ; Tolosa E; Canesi M; Post B; Nonnekes J; Bloem BR;
    Parkinsonism Relat Disord; 2018 Nov; 56():33-40. PubMed ID: 29910157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Midbrain and pons MRI shape analysis and its clinical and CSF correlates in degenerative parkinsonisms: a pilot study.
    Painous C; Pascual-Diaz S; Muñoz-Moreno E; Sánchez V; Pariente JC; Prats-Galino A; Soto M; Fernández M; Pérez-Soriano A; Camara A; Muñoz E; Valldeoriola F; Caballol N; Pont-Sunyer C; Martin N; Basora M; Tio M; Rios J; Martí MJ; Bargalló N; Compta Y
    Eur Radiol; 2023 Jul; 33(7):4540-4551. PubMed ID: 36773046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.
    Jabbari E; Woodside J; Guo T; Magdalinou NK; Chelban V; Athauda D; Lees AJ; Foltynie T; Houlden H; Church A; Hu MT; Rowe JB; Zetterberg H; Morris HR
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):768-773. PubMed ID: 30867224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.